Tesaro Inc. (NASDAQ:TSRO) was upgraded by Bank of America Corp. from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday.

A number of other equities analysts have also recently weighed in on TSRO. Zacks Investment Research cut Tesaro from a “hold” rating to a “sell” rating in a report on Wednesday, June 15th. FBR & Co upped their price target on Tesaro from $65.00 to $93.00 and gave the stock an “outperform” rating in a report on Wednesday, June 29th. Jefferies Group cut Tesaro from a “buy” rating to a “hold” rating and upped their price target for the stock from $53.00 to $75.00 in a report on Thursday, June 30th. They noted that the move was a valuation call. Leerink Swann upped their price target on Tesaro from $65.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, June 30th. Finally, Mizuho reaffirmed an “outperform” rating and issued a $67.00 target price on shares of Tesaro in a research report on Thursday, June 30th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Tesaro presently has an average rating of “Buy” and an average price target of $101.19.

Analyst Recommendations for Tesaro (NASDAQ:TSRO)

Tesaro (NASDAQ:TSRO) opened at 99.26 on Monday. Tesaro has a 12 month low of $29.51 and a 12 month high of $110.48. The stock’s 50 day moving average is $96.42 and its 200-day moving average is $68.96. The stock’s market capitalization is $5.10 billion.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.71) by $0.43. The firm earned $36.60 million during the quarter, compared to analysts’ expectations of $4.98 million. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. During the same quarter in the prior year, the business earned ($1.51) EPS. On average, equities research analysts expect that Tesaro will post ($7.36) earnings per share for the current year.

In other Tesaro news, VP Jeffrey H. Hanke sold 29,166 shares of the stock in a transaction on Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total value of $2,509,442.64. Following the sale, the vice president now directly owns 29,166 shares of the company’s stock, valued at $2,509,442.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Martin H. Jr. Huber sold 408 shares of the stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total value of $44,112.96. Following the completion of the sale, the senior vice president now directly owns 1,250 shares in the company, valued at $135,150. The disclosure for this sale can be found here. 40.50% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in Tesaro by 13.3% in the first quarter. BlackRock Inc. now owns 7,096 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 834 shares during the last quarter. BlackRock Group LTD boosted its position in Tesaro by 7.9% in the first quarter. BlackRock Group LTD now owns 162,499 shares of the biopharmaceutical company’s stock valued at $7,154,000 after buying an additional 11,880 shares during the last quarter. BlackRock Fund Advisors boosted its position in Tesaro by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,293,906 shares of the biopharmaceutical company’s stock valued at $56,971,000 after buying an additional 23,384 shares during the last quarter. State Street Corp boosted its position in Tesaro by 0.7% in the first quarter. State Street Corp now owns 893,749 shares of the biopharmaceutical company’s stock valued at $39,349,000 after buying an additional 6,026 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its position in Tesaro by 35.8% in the first quarter. Pictet Asset Management Ltd. now owns 55,000 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 14,500 shares during the last quarter. 88.81% of the stock is currently owned by hedge funds and other institutional investors.

Tesaro Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Stock Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related stocks with our FREE daily email newsletter.